Key Differences Between Avibactam and Tazobactam
Avibactam is a non-β-lactam β-lactamase inhibitor with broader spectrum activity against Class A, C, and some Class D β-lactamases (including KPCs and ESBLs), while tazobactam is a β-lactam-based inhibitor primarily active against Class A enzymes only 1, 2.
Mechanism and Chemical Structure
Avibactam
- Non-β-lactam structure: Does not contain a β-lactam ring, making it fundamentally different from traditional inhibitors
- Mechanism: Covalently binds to β-lactamases through a reversible mechanism, allowing it to "recycle" and inhibit multiple enzyme molecules 1
- No intrinsic antibacterial activity: Has minimal affinity for penicillin-binding proteins (PBPs) and therefore no direct antibacterial effect 1
Tazobactam
- β-lactam structure: Contains a β-lactam ring similar to penicillins
- Mechanism: Irreversibly binds to β-lactamases but is consumed in the process
- Some intrinsic activity: Has reduced but measurable affinity for PBPs, which may contribute to activity against certain organisms like Acinetobacter baumannii 3
Spectrum of β-Lactamase Inhibition
Avibactam - Broader Coverage
- Class A: ESBLs (TEM, SHV, CTX-M), Klebsiella pneumoniae carbapenemases (KPCs) 1
- Class C: AmpC β-lactamases 1
- Class D: Certain OXA enzymes (including OXA-48) 4
- Does NOT inhibit: Metallo-β-lactamases (Class B, including NDM) 1, 5
Tazobactam - Narrower Coverage
- Class A: Some ESBLs and penicillinases (Richmond-Sykes class III, Bush class 2b & 2b') 2
- Limited activity: Variable against Class II and IV penicillinases 2
- Does NOT inhibit: KPCs, most AmpC enzymes, OXA enzymes, or metallo-β-lactamases 6, 5
Clinical Activity Against Resistant Pathogens
Carbapenem-Resistant Enterobacterales (CRE)
Avibactam combinations are superior for KPC-producing CRE: Ceftazidime-avibactam demonstrates 89.4% susceptibility against CRE, primarily driven by excellent activity against KPC producers (69.2% of CRE) 7. The 2022 ESCMID guidelines suggest ceftazidime-avibactam as a preferred agent for severe CRE infections 8.
Tazobactam combinations have limited CRE activity: Piperacillin-tazobactam shows poor activity against KPC-producing organisms and is not recommended for CRE 6, 5.
ESBL-Producing Enterobacterales
Avibactam demonstrates superior ESBL coverage: When combined with piperacillin at equivalent doses, avibactam achieved 61.4%-73.6% time above MIC compared to tazobactam's 13.5%-44.5% against ESBL-producing isolates 6. This translates to better bacterial suppression in hollow-fiber models 6.
Pseudomonas aeruginosa
Both inhibitors retain activity against P. aeruginosa, though through different partner β-lactams:
- Ceftolozane-tazobactam: Recommended by ESCMID for difficult-to-treat resistant P. aeruginosa (DTR-PA) 8
- Ceftazidime-avibactam: Also active against DTR-PA, with 79.1% of isolates susceptible 7
The choice depends on local resistance patterns and specific β-lactamase mechanisms present.
Acinetobacter baumannii
Critical distinction: Tazobactam shows some activity against A. baumannii due to its β-lactam structure allowing PBP binding, while avibactam demonstrates no activity 3. However, ESCMID conditionally recommends against cefiderocol (not avibactam) for CRAB, and neither agent is a primary option for this pathogen 8.
Pharmacokinetic Differences
Avibactam
- Renal elimination: Primarily unchanged in urine via OAT1 and OAT3 transporters 1
- No CYP metabolism: Not metabolized by cytochrome P450 enzymes 1
- Drug interactions: Probenecid inhibits OAT-mediated transport; co-administration not recommended 1
Tazobactam
- Renal elimination: Primarily unchanged, with some metabolite formation 2
- Dialysis considerations: 30-40% removed by hemodialysis (vs. avibactam data not specified in detail) 2
- Minimal drug interactions: No significant CYP interactions 2
Clinical Implications and Stewardship
When to Choose Avibactam Combinations
Use for suspected or confirmed KPC-producing CRE: This is the primary advantage over tazobactam combinations 8, 4. Ceftazidime-avibactam is included in the WHO Essential Medicines List under the "reserve" category for this indication 9.
Consider for ESBL infections when tazobactam fails: In vitro and animal model data support superior activity 6.
When Tazobactam Combinations Remain Appropriate
Non-carbapenemase-producing infections: For community-acquired or healthcare-associated infections without KPC/ESBL mechanisms, piperacillin-tazobactam remains effective and more cost-effective 2.
Broader Gram-positive coverage needed: Piperacillin-tazobactam covers MSSA and some anaerobes, while ceftazidime-avibactam requires combination with metronidazole for anaerobic coverage 8, 1.
Critical Limitations
Both Agents Lack MBL Activity
Neither avibactam nor tazobactam inhibits metallo-β-lactamases (NDM, VIM, IMP) 1, 5. For MBL-producing CRE, ESCMID suggests aztreonam plus ceftazidime-avibactam combination therapy, where avibactam protects aztreonam from other β-lactamases while aztreonam remains stable to MBLs 8, 10.
Resistance Development
Both agents can select for resistance, though mechanisms differ. Avibactam resistance in KPC producers often involves mutations in the β-lactamase itself, while tazobactam resistance typically involves β-lactamase overproduction or acquisition of additional resistance mechanisms 5, 4.
Practical Algorithm for Selection
Identify suspected resistance mechanism:
Consider infection site and required coverage:
- Intra-abdominal infection needing anaerobic coverage → Piperacillin-tazobactam OR ceftazidime-avibactam + metronidazole
- Pneumonia with P. aeruginosa → Ceftolozane-tazobactam or ceftazidime-avibactam based on susceptibility 8
Apply stewardship principles: